Abstract:e12625 Background: Individual tumors of breast cancer patients possess unique characteristics that may influence their neoadjuvant therapy (NAT) response to specific cytotoxic agents and treatment choices. Therefore, it is essential to have a platform that can assist in the personalized selection of chemotherapy for individual patients. Previously, we reported an in vitro model called patient-derived tumor-like cell clusters (PTC), which can structurally and functionally recapitulate original tumors. Retrospective research has shown that PTC hold potential as reliable pre-clinical drug testing model for guiding NAT therapeutic options in early breast cancer patients. Methods: This prospective, phase II, open-label study aimed to validate the efficacy of drug screening on patient-derived tumor-like cell clusters (PTCs). TNBC and HER2 positive patients received neoadjuvant therapy based on subtype and personalized drug testing on PTCs. TNBC patients were treated based on drug testing, receiving either TA (taxanes combined with anthracyclines) or TP (taxanes combined with carboplatin). HER2 positive patients received treatment based on drug testing, including THP (taxanes, trastuzumab and pertuzumab) or TCbHP (taxanes, carboplatin, trastuzumab, and pertuzumab). Sample size calculation was performed using Fleming's two-stage design. For TNBC patients, if 10 or more out of 20 patients achieved pCR in the first stage, an additional 26 patients would be enrolled in the second stage. For HER2-positive patients, the sample size was same with TNBC patients. The study was approved by the Ethics Committee of Peking University People's Hospital in Beijing and was registered on ClinicalTrials.gov (NCT04750122, NCT04836156). This time, we report the results of the first stage. Results: Among 20 enrolled TNBC patients in the first stage, 15 achieved pCR with the rate of 75%. 17 patients (85%) had RCB 0-I score while 3 patients (15%) had an RCB-II score. 14 patients received TP as it demonstrated greater sensitivity in vitro. Out of these 14 patients, 10 patients (71.4%) achieved pCR. Six patients received TA as it was more effective in drug testing. Among these patients, 5 (83.3%) patients achieved pCR. Out of 20 enrolled HER2-positive patients, 16 achieved pCR, resulting in a pCR rate of 80%. Six patients received THP treatment based on their sensitivity to this regimen in drug testing. Among these patients, 5 (83.3%) achieved a pCR. 14 patients who were sensitive to TCbHP but not to THP in drug testing received TCbHP treatment. Among these patients, 11 (78.6%) achieved pCR. The non-pCR patients had 2 RCB-II score and the ORR was 100% for all 14 patients. Conclusions: Our results demonstrate that personalized drug testing on PTCs can effectively guide the choice of neoadjuvant therapy for early TNBC and HER2-positive breast cancer patients. Clinical trial information: NCT04750122 , NCT04836156 .

A Feasibility and Safety Study of Concurrent Chemotherapy Based on Genetic Testing in Patients with High-Risk Salivary Gland Tumors

Oncological Outcome of Patients with Salivary Gland Cancer Treated with Surgery and Postoperative Intensity-Modulated Radiotherapy: a Retrospective Study

Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy for Patients with High-Risk Malignant Salivary Gland Tumors

A Phase II Umbrella Clinical Trial of Advanced Salivary Gland Cancer Based on Molecular Typing.

Clinical Benefit of Gemcitabine Plus Cisplatin 3-Week Regimen for Patients with Advanced Non-Small Cell Lung Cancer: a Prospective Observational Study.

Molecular Characterization and Prognostic Analysis of Non-Small Cell Lung Cancer: A Single Centric Real-World Study.

A Retrospective Analysis to Explore the Value of Gemcitabine Combined with Cisplatin As Adjuvant Chemotherapy of NSCLC

Efficacy and Safety of First-Line Platinum-Based Doublet Chemotherapy in Advanced Primary Pulmonary Salivary Gland Tumors (PSGTs)

Postoperative radiotherapy with docetaxel versus cisplatin for high-risk oral squamous cell carcinoma: a randomized phase II trial with exploratory analysis of ITGB1 as a potential predictive biomarker

Tolerability, Efficacy and Feasibility of Concurrent Gemcitabine and Cisplatin (CGP) Combined With Intensity Modulated Radiotherapy for Loco-Regionally Advanced Carcinoma of the Cervix

Chinese multicenter randomized trial of customized chemotherapy based on BRCA1 (breast cancer susceptibility gene 1)-RAP80 (receptora-ssociaet d protein 80) mRNA expr ession ina dvanced non-small cell lu ng cancer (NSCLC) pa tients

Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1

Neoadjuvant tislelizumab combined with APF for patients with locally advanced head and neck squamous cell carcinoma: A prospective single-arm clinical trial.

Serial Circulating Tumor Dna Analysis Indicating The Efficacy And Prognosis Of Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer.

Comprehensive Genomic Analysis of Salivary Gland Carcinomas in a Chinese Population

A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).

A Prospective Phase II Study of Neoadjuvant Therapy Guided by Personalized Drug-Testing on Patient-Derived Tumor-Like Cell Clusters for Early Breast Cancer.

Clinical Study on Sensitivity of Oral and Maxillofacial Cancers with Chemotherapy

Genomic Profiling Reveals Novel Predictive Biomarkers for Chemo-Radiotherapy Efficacy and Thoracic Toxicity in Non-Small-Cell Lung Cancer

Concomitant Chemoradiotherapy Using Pemetrexed and Carboplatin for Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): Preliminary Results of a Phase II Study

Concurrent chemoradiation with low-dose and long-duration weekly infusion of gemcitabine in unresectable squamous cell carcinoma of head and neck (SCCHN)